Ernexa Therapeutics Inc. (ERNA)

Nasdaq: ERNA · Pharmaceutical Preparations · Cambridge, MA · filing with the SEC since 1994

Full chart Alerts Compare

Grade3.0

◀ Past 1.2● Present 1.7▶ Future 5.1

2 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of Ernexa Therapeutics Inc.

Nine metrics read from its own filings, by tense

Headline grade

3.0/10

◀ Past1.225% of the headline

● Present1.735% of the headline

▶ Future5.140% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

1.2/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

0.5/10

Has it survived what it has been through?

30 warning events since 2017; the latest 2026-03-20.

weight 22% of this tense · 5th percentile among 497 sector filers · read for itself

From the record

Ernexa Therapeutics Inc.'s filings since 2017 show 30 warning events of 4 kinds: a notice about its exchange listing (8-K item 3.01, 21 times, the latest 2026-03-20); a warning not to rely on past financial statements (8-K item 4.02, the latest 2022-06-17); an auditor change (8-K item 4.01, 6 times, the latest 2025-07-07); a late-report notice (Form NT 10-K or NT 10-Q, 2 times, the latest 2022-05-17) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

1.4/10

What has it actually done, year after year?

-31.6% a year over 10 filed years; profitable in 0 of 9.

weight 45% of this tense · 14th percentile among 323 sector filers · read for its customers

From the record

Ernexa Therapeutics Inc.'s 10 filed years say what it did: revenue went from $26 million in fiscal 2014 to $582 thousand in fiscal 2024, down 31.6% a year; it rose in 2 of 8 years; the deepest fall was 100% from fiscal 2014 to fiscal 2022; net income was positive in 0 of 9 of those years (its annual reports).

What it rests on

revenue growth over the filed span-31.6%bottom 9% of its family
the share of years revenue rosebottom 11% of its family
the share of filed years with a profitbottom 27% of its family
the deepest fall from a revenue peak100.0%bottom 10% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

1.4/10

How has it treated the people who own it?

SI estimate 1.4/10, confidence 35 of 100 (one part).

weight 33% of this tense · 14th percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the bottom 14% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Ernexa Therapeutics Inc.'s shareholder treatment is put at 1.4 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 14% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

1.7/1035% of the headline grade · 3 of 3 filed

Financial health

as filed

1.4/10

Is it financially healthy right now?

ROE -587%: lost 587¢ per shareholder dollar. Leverage 59%: owes 59¢ per asset dollar.

weight 45% of this tense · 14th percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Ernexa Therapeutics Inc. lost about 587 cents for every dollar of shareholders' money. Leverage: it owed about 59 cents per dollar of assets, and net share issuance: its share count grew 593.1% over the year (the filed statements).

What it rests on

what it owes per dollar of assetsbottom 29% of its family
return on equitybottom 3% of its family
the share count against the year beforebottom 9% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

1.4/10

How strong is its position in its industry?

bottom 14% of 315 in its family; net margin -7652.7%.

weight 22% of this tense · 14th percentile among 315 sector filers · read for its customers

From the record

Ernexa Therapeutics Inc.'s standing among 315 graded names in its industry family: revenue of $582 thousand in fiscal 2024 ranks in the bottom 18% by size; a net margin of -7652.7% ranks in the bottom 12%; revenue growth of -43.7% a year over the last 3 filed years ranks in the bottom 11% (its annual reports).

What it rests on

revenue against the family$582,000bottom 18% of its family
net margin-7652.7%bottom 12% of its family
three-year revenue growth-43.7%bottom 11% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed

2.5/10

What are the people in charge doing?

bottom 25% of 315 in its family for leadership; chief executive since 2024.

weight 33% of this tense · 25th percentile among 315 sector filers · read for its shareholders

From the record

Ernexa Therapeutics Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Luther, Sanjeev (President and CEO, as filed), filing under that title since 2024-01-03, 2.9 years (bottom 31% of its family); the 8 officers and directors filing in the last fifteen months have been on the record a median of 2.8 years (bottom 14%); 5 officer or director changes were reported on Form 8-K since 2023-11-13, against the 8 people in charge now (bottom 31%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

officer and director changes on Form 8-K, against the people in charge5 in three years among 8 peoplebottom 31% of its family
the median years the people in charge have filed2.8 yearsbottom 14% of its family
the chief executive's years on the record2.9 yearsbottom 31% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

5.1/1040% of the headline grade · 2 of 3 filed, 1 estimated

Room to expand

SI estimate

5.5/10

How much room does it have to grow?

SI estimate 5.5/10, confidence 35 of 100 (one part).

weight 33% of this tense · 55th percentile among 479 sector filers · read for itself

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, cash less debt against assets, which ranks in the top 45% of 479 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue.
What the record cannot read: The record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue.
How it was reasoned: one part: cash less debt against assets, the one part on file, ranked among 479 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Ernexa Therapeutics Inc.'s room to expand is put at 5.5 of 10 with a confidence of 35 of 100, because read from one part only, cash less debt against assets, which ranks in the top 45% of 479 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue. A filing that carries the missing parts replaces this estimate with the filed reading.

Growth drivers

as filed

4.1/10

What could actually drive growth from here?

bottom 41% of 306 in its family for growth drivers.

weight 45% of this tense · 41st percentile among 306 sector filers · read for its customers

From the record

Ernexa Therapeutics Inc.'s growth drivers, from the filed years to fiscal 2024: revenue grew -43.7% a year over the last three filed years against -31.6% over all 10, slowing (bottom 31% of its family); the newest year grew 752.1% (top 5%); research spending grew -26.3% a year (bottom 16%); capital spending grew -50% a year (bottom 21%) (its annual reports). Ernexa Therapeutics Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

three-year growth against the whole span-12.1 points a yearbottom 31% of its family
the newest year's revenue growth752.1%top 5% of its family
three-year growth of research spending-26.3%bottom 16% of its family
three-year growth of capital spending-50.0%bottom 21% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed

6.7/10

Did its newest year beat what its own record pointed to?

top 33% of 233 in its family for expectations against reality.

weight 22% of this tense · 67th percentile among 233 sector filers · read for its shareholders

From the record

Ernexa Therapeutics Inc.'s newest year against its own record: revenue of $582 thousand in fiscal 2024 came in 3671.3% above the $15 thousand its prior three years' pace pointed to (top 2% of its family); net income of $45 million against a prior three-year average of $18 million (bottom 10%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 7%) (its annual reports).

What it rests on

revenue against the prior three years' pace3671.3%top 2% of its family
net income against the prior three years' average-150%bottom 10% of its family
net margin against its prior averageup more than 100 pointstop 7% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton ERNA · research, not advice